Thermo Fisher Scientific Reports Strong Q4 Earnings Amid Market Decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 29 2026
0mins
Should l Buy TMO?
Source: seekingalpha
Thermo Fisher Scientific Inc's stock has dropped 3.00% and hit a 20-day low amid a broader market decline, with the Nasdaq-100 down 0.69% and the S&P 500 down 0.76%.
Despite the stock's decline, Thermo Fisher reported strong Q4 2025 earnings with a revenue of $12.21 billion, a 7% year-over-year increase, and an adjusted EPS of $6.57. The company also announced a strategic acquisition of Clario for approximately $9 billion, expected to enhance profitability and add $0.45 to adjusted EPS, reflecting its proactive growth strategy.
The strong financial performance and strategic initiatives position Thermo Fisher well for future growth, even as the overall market experiences weakness.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TMO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TMO
Wall Street analysts forecast TMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMO is 658.89 USD with a low forecast of 580.00 USD and a high forecast of 750.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 542.360
Low
580.00
Averages
658.89
High
750.00
Current: 542.360
Low
580.00
Averages
658.89
High
750.00
About TMO
Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. It also provides purification and filtration technologies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
OpenAI Launches New Enterprise Platform Frontier to Enhance AI Integration
- Platform Launch: OpenAI announced the launch of its new enterprise platform, Frontier, designed to streamline the management and deployment of AI agents by integrating disparate systems and data within organizations, thereby enhancing operational efficiency for business customers.
- Accelerated Market Penetration: Currently, OpenAI has over 1 million enterprise customers, with expectations to increase the proportion of enterprise clients from 40% to nearly 50% by year-end, indicating strong growth potential in the enterprise market.
- Collaborative Ecosystem: OpenAI emphasizes that the Frontier platform will be built in collaboration with various partners, supporting both self-built agents by enterprises and those from third parties like Google, Microsoft, and Anthropic, showcasing the company's openness and flexibility within the AI ecosystem.
- Initial User Feedback: Frontier is initially being rolled out to a select group of customers, including Uber, State Farm, Intuit, and Thermo Fisher, with broader availability expected in the coming months, which is likely to further drive enterprise transformation and upgrades in AI applications.
See More
OpenAI Launches New Enterprise Platform Frontier
- Enterprise Customer Growth: OpenAI CFO Sarah Friar noted that enterprise customers currently account for 40% of the company's business, with expectations to reach 50% by year-end, indicating successful execution of its expansion strategy in the enterprise market.
- Frontier Platform Features: The newly launched Frontier platform acts as an intelligence layer that integrates disparate systems and data within organizations, simplifying the management and deployment of AI agents, thereby enhancing operational efficiency and task execution capabilities.
- Partner Ecosystem: OpenAI CEO Fidji Simo emphasized that the launch of Frontier reflects the necessity of collaborating with an ecosystem, as enterprises require diverse partners to meet their AI needs, showcasing OpenAI's flexibility and adaptability in the market.
- Initial User Feedback: The Frontier platform has been rolled out to a select few customers, including Uber, State Farm, Intuit, and Thermo Fisher, with broader availability expected in the coming months, signaling OpenAI's deeper penetration into the enterprise market.
See More
C WorldWide Increases Stake in MercadoLibre by 517%
- Stake Increase: C WorldWide Group Holding A/S purchased an additional 44,747 shares of MercadoLibre in Q4 2026, with an estimated transaction value of approximately $93.99 million, indicating strong confidence in the Latin American market.
- Position Value Growth: The fund's quarter-end position value in MercadoLibre increased by $87.34 million, reflecting positive market expectations for the company despite its stock underperforming over the past year.
- Competitive Pressure: While MercadoLibre faces competitive pressures from Amazon and others, its fintech arm is actively addressing the rise in nonperforming loans, demonstrating the company's resilience in challenging conditions.
- Economic Recovery Opportunities: The rapid improvement in Argentina's economy and leadership changes in Venezuela may present new growth opportunities for MercadoLibre, and although its P/E ratio stands at 51, it remains attractive compared to Amazon's historical multiples.
See More
Revvity Reports Strong Q4 2025 Earnings, Exceeds Expectations
- Earnings Growth: Revvity reported adjusted earnings of $1.70 per share for Q4 2025, a 19.7% year-over-year increase that surpassed the consensus estimate of $1.55, indicating robust profitability and competitive strength.
- Sales Increase: The company achieved sales of $772.06 million, up 6% year-over-year with 4% organic growth, exceeding the market expectation of $761.29 million, reflecting sustained demand for its products in the market.
- Life Sciences Segment Performance: The Life Sciences segment generated $382 million in revenue, a 2% increase, although academic and government demand declined, the growth from pharma and biotech partially offset this, showcasing the segment's resilience.
- Future Guidance: Revvity forecasts adjusted earnings for fiscal 2026 to be between $5.35 and $5.45 per share, with sales projected at $2.96 billion to $2.99 billion, reflecting a year-over-year growth of 4%-5%, indicating the company's confidence and strategic planning for future market conditions.
See More
Thermo Fisher Scientific Q4 2025 Earnings Highlights
- Strong Financial Performance: Thermo Fisher reported Q4 2025 revenue of $12.21 billion, a 7% year-over-year increase, with adjusted EPS at $6.57, reflecting excellent execution and operational performance throughout the year.
- Innovative Product Launches: The company introduced several new products, including the Thermo Scientific Orbitrap Astral Zoom, receiving extremely positive customer feedback, which is expected to accelerate research and enhance scientific breakthroughs, thereby solidifying its market position.
- Strategic Acquisition Plans: Thermo Fisher announced the acquisition of Clario for approximately $9 billion, expected to close by mid-2026, which is projected to add $0.45 to adjusted EPS, demonstrating the company's proactive approach to expanding its business and enhancing profitability.
- 2026 Financial Guidance: The company initiated revenue guidance for 2026 between $46.3 billion and $47.2 billion, with adjusted EPS projected at $24.22 to $24.80, reflecting confidence in future growth while remaining mindful of macroeconomic uncertainties.
See More
Thermo Fisher Reports Strong Q4 2025 Earnings Beat
- Earnings Beat: Thermo Fisher reported adjusted Q4 2025 earnings of $6.57 per share, surpassing the expected $6.45, demonstrating robust performance amid a challenging external environment.
- Significant Sales Growth: Quarterly sales reached $12.22 billion, a 7% year-over-year increase, exceeding analyst consensus of $11.95 billion, indicating sustained competitive strength in the market.
- Strong Segment Performance: Life Sciences Solutions sales rose 13.1% to $2.95 billion, while Laboratory Products and Biopharma Services sales increased 7.5% to $6.38 billion, reflecting the effectiveness of strategic investments in key areas.
- Optimistic 2026 Outlook: The company projects 2026 revenue growth of 4%-6%, targeting $46.3-$47.2 billion, with adjusted earnings expected between $24.22 and $24.80 per share, showcasing strong growth potential and market confidence.
See More
OpenAI Launches New Enterprise Platform Frontier to Enhance AI Integration
- Platform Launch: OpenAI announced the launch of its new enterprise platform, Frontier, designed to streamline the management and deployment of AI agents by integrating disparate systems and data within organizations, thereby enhancing operational efficiency for business customers.
- Accelerated Market Penetration: Currently, OpenAI has over 1 million enterprise customers, with expectations to increase the proportion of enterprise clients from 40% to nearly 50% by year-end, indicating strong growth potential in the enterprise market.
- Collaborative Ecosystem: OpenAI emphasizes that the Frontier platform will be built in collaboration with various partners, supporting both self-built agents by enterprises and those from third parties like Google, Microsoft, and Anthropic, showcasing the company's openness and flexibility within the AI ecosystem.
- Initial User Feedback: Frontier is initially being rolled out to a select group of customers, including Uber, State Farm, Intuit, and Thermo Fisher, with broader availability expected in the coming months, which is likely to further drive enterprise transformation and upgrades in AI applications.
See More
OpenAI Launches New Enterprise Platform Frontier
- Enterprise Customer Growth: OpenAI CFO Sarah Friar noted that enterprise customers currently account for 40% of the company's business, with expectations to reach 50% by year-end, indicating successful execution of its expansion strategy in the enterprise market.
- Frontier Platform Features: The newly launched Frontier platform acts as an intelligence layer that integrates disparate systems and data within organizations, simplifying the management and deployment of AI agents, thereby enhancing operational efficiency and task execution capabilities.
- Partner Ecosystem: OpenAI CEO Fidji Simo emphasized that the launch of Frontier reflects the necessity of collaborating with an ecosystem, as enterprises require diverse partners to meet their AI needs, showcasing OpenAI's flexibility and adaptability in the market.
- Initial User Feedback: The Frontier platform has been rolled out to a select few customers, including Uber, State Farm, Intuit, and Thermo Fisher, with broader availability expected in the coming months, signaling OpenAI's deeper penetration into the enterprise market.
See More
C WorldWide Increases Stake in MercadoLibre by 517%
- Stake Increase: C WorldWide Group Holding A/S purchased an additional 44,747 shares of MercadoLibre in Q4 2026, with an estimated transaction value of approximately $93.99 million, indicating strong confidence in the Latin American market.
- Position Value Growth: The fund's quarter-end position value in MercadoLibre increased by $87.34 million, reflecting positive market expectations for the company despite its stock underperforming over the past year.
- Competitive Pressure: While MercadoLibre faces competitive pressures from Amazon and others, its fintech arm is actively addressing the rise in nonperforming loans, demonstrating the company's resilience in challenging conditions.
- Economic Recovery Opportunities: The rapid improvement in Argentina's economy and leadership changes in Venezuela may present new growth opportunities for MercadoLibre, and although its P/E ratio stands at 51, it remains attractive compared to Amazon's historical multiples.
See More
Revvity Reports Strong Q4 2025 Earnings, Exceeds Expectations
- Earnings Growth: Revvity reported adjusted earnings of $1.70 per share for Q4 2025, a 19.7% year-over-year increase that surpassed the consensus estimate of $1.55, indicating robust profitability and competitive strength.
- Sales Increase: The company achieved sales of $772.06 million, up 6% year-over-year with 4% organic growth, exceeding the market expectation of $761.29 million, reflecting sustained demand for its products in the market.
- Life Sciences Segment Performance: The Life Sciences segment generated $382 million in revenue, a 2% increase, although academic and government demand declined, the growth from pharma and biotech partially offset this, showcasing the segment's resilience.
- Future Guidance: Revvity forecasts adjusted earnings for fiscal 2026 to be between $5.35 and $5.45 per share, with sales projected at $2.96 billion to $2.99 billion, reflecting a year-over-year growth of 4%-5%, indicating the company's confidence and strategic planning for future market conditions.
See More
Thermo Fisher Scientific Q4 2025 Earnings Highlights
- Strong Financial Performance: Thermo Fisher reported Q4 2025 revenue of $12.21 billion, a 7% year-over-year increase, with adjusted EPS at $6.57, reflecting excellent execution and operational performance throughout the year.
- Innovative Product Launches: The company introduced several new products, including the Thermo Scientific Orbitrap Astral Zoom, receiving extremely positive customer feedback, which is expected to accelerate research and enhance scientific breakthroughs, thereby solidifying its market position.
- Strategic Acquisition Plans: Thermo Fisher announced the acquisition of Clario for approximately $9 billion, expected to close by mid-2026, which is projected to add $0.45 to adjusted EPS, demonstrating the company's proactive approach to expanding its business and enhancing profitability.
- 2026 Financial Guidance: The company initiated revenue guidance for 2026 between $46.3 billion and $47.2 billion, with adjusted EPS projected at $24.22 to $24.80, reflecting confidence in future growth while remaining mindful of macroeconomic uncertainties.
See More
Thermo Fisher Reports Strong Q4 2025 Earnings Beat
- Earnings Beat: Thermo Fisher reported adjusted Q4 2025 earnings of $6.57 per share, surpassing the expected $6.45, demonstrating robust performance amid a challenging external environment.
- Significant Sales Growth: Quarterly sales reached $12.22 billion, a 7% year-over-year increase, exceeding analyst consensus of $11.95 billion, indicating sustained competitive strength in the market.
- Strong Segment Performance: Life Sciences Solutions sales rose 13.1% to $2.95 billion, while Laboratory Products and Biopharma Services sales increased 7.5% to $6.38 billion, reflecting the effectiveness of strategic investments in key areas.
- Optimistic 2026 Outlook: The company projects 2026 revenue growth of 4%-6%, targeting $46.3-$47.2 billion, with adjusted earnings expected between $24.22 and $24.80 per share, showcasing strong growth potential and market confidence.
See More
